Measurement of anti-factor xa activity in patients on apixaban for non-valvular atrial fibrillation

Circulation Journal

Volumn 79, Issue 12, 2015, Pages 2584-2590

  Osanai, Hiroyuki ^a   Ajioka, Masayoshi ^a   Masutomi, Tomohiro ^a   Kuwayama, Tasuku ^a   Ishihama, Sota ^a   Sakamato, Yusuke ^a   Otaka, Naoya ^a   Sakaguchi, Teruhiro ^a   Inoue, Yosuke ^a   Kanbara, Takahiro ^a   Nakashima, Yoshihito ^a   Asano, Hiroshi ^a   Sakai, Kazuyoshi ^a  

^a TOSEI GENERAL HOSPITAL   (Japan)

Author keywords

Anti factor Xa activity; Apixaban; Atrial fibrillation

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BLOOD CLOTTING FACTOR 10A; CILOSTAZOL; CLOPIDOGREL; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GINGIVA BLEEDING; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; NONVALVULAR ATRIAL FIBRILLATION; OBSERVATIONAL STUDY; PHARMACODYNAMICS; AGE; BLOOD; DOSE RESPONSE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; PYRAZOLES; PYRIDONES;

EID: 84978971705     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0470     Document Type: Article

References (20)

1. Granger CB, Alexander JH, McMurray JV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981 - 992.
2. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806 - 817.
3. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with nonvalvular atrial fibrillation: The ARISTOTLE-J study. Circ J 2011; 75: 1852 - 1859.
4. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (2013): Digest version. Circ J 2014; 78: 1997 - 2021.
5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139 - 1151.
6. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883 - 891.
7. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; J-ROCKET AF Study Investigators. Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age. Circ J 2014; 786: 1349 - 1356.
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093 - 2104.
9. Cuker A, Deborah M, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014; 64: 1128 - 1139.
10. Kanemoto M, Kuhara H, Ueda T, Shinohara T, Oda T, Nakao F, et al. Association of apixaban therapy and prothrombin time in patients with atrial fibrillation. Circ J 2014; 78: 2651 - 2656.
11. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: A practical laboratory guide. Thromb Haemost 2013; 110: 283 - 294.
12. Barrett Y, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263 - 1271.
13. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban: An oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis 2011; 32: 183 - 187.
14. Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692 - 694.
15. Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014; 6: 179 - 187.
16. Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 2013; 76: 908 - 916.
17. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76: 776 - 786.
18. Frost C, Wang J, Nepal S, Schuster A, Barret YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2012; 75: 476 - 487.
19. Barco S, Cheung YW, Eikelboom JW, Coppens M. New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol 2013; 26: 215 - 224.
20. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al; J-ROCKET AF Study Investigators. Safety and Efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: Subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 2013; 77: 632 - 638.